HE4, CA-125, ROMA INDEX, AND TUMOR RECEPTOR EXPRESSION IN POSTMENOPAUSAL OVARIAN AND CERVICAL CANCER

Authors:

Abstract:

Ovarian and cervical cancers are among the most common gynecologic malignancies in postmenopausal women, and reliable biomarkers are essential for accurate diagnosis and risk stratification. The study aims to evaluate the clinical relevance of serum HE4 and CA-125 levels, the ROMA index, and tumor receptor expression (ER, PR, HER2, Ki-67) in postmenopausal patients with ovarian and cervical cancer. A total of 45 postmenopausal ovarian cancer patients (age Me=58.4) and 38 postmenopausal cervical cancer patients (Me=59.3;) were enrolled. Serum HE4 and CA-125 were measured using the fully automated Integra 411 analyzer. Tumor receptor status (ER, HR, HER2, Ki-67) was evaluated by immunohistochemistry. ROMA index was calculated for ovarian cancer patients. Elevated levels of HE4 and CA-125 were observed in both ovarian and cervical cancer patients. In ovarian cancer patients, circulating tumor biomarkers increased markedly with tumor progression. HE4 demonstrated a strong positive correlation with CA-125 and the ROMA index, indicating a close association between these biomarkers in ovarian malignancy. Additionally, HE4 showed moderate correlations with tumor receptor expression, including ER, PR, HER2, and the proliferative marker Ki-67, suggesting a link between biomarker levels and tumor biological activity. In cervical cancer patients, HE4 and CA-125 also exhibited moderate correlations with receptor expression and Ki-67, reflecting a similar pattern of association between circulating biomarkers and tumor characteristics. Overall, the ROMA index effectively differentiated high-risk ovarian cancer patients from lower-risk groups and showed a strong association with HE4 levels. Integrated analysis of HE4, CA-125, ROMA index, and receptor expression may improve early detection, risk assessment, and individualized treatment in postmenopausal patients with ovarian and cervical cancer.

Keywords:

ovarian cancer cervical cancer human epididymis protein 4 cancer antigen 125 ROMA index estrogen receptor progesterone receptor human epidermal growth factor receptor 2 Ki-67 proliferation index

References:

1. Ahmed AA, Abdou AM. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels. Curr Probl Cancer. 2019 Oct;43(5):450-460. doi: 10.1016/j.currproblcancer.2018.12.004.
2. Barr CE, Funston G, Jeevan D, Sundar S, Mounce LTA, Crosbie EJ. The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population. Cancers (Basel). 2022 Apr 24;14(9):2124. doi: 10.3390/cancers14092124.
3. Braicu EI, Krause CL, Torsten U, Mecke H, Richter R, Hellmeyer L, et al. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients. BMC Cancer. 2022 Jul 30;22(1):831. doi: 10.1186/s12885-022-09887-5.
4. Chudecka-Głaz A, Strojna A, Michalczyk K, Wieder-Huszla S, Safranow K, Skwirczyńska E, et al. Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy. Diagnostics (Basel). 2023 Jan 26;13(3):452. doi: 10.3390/diagnostics13030452.
5. Guo M, Liang L, Wu L, Xie D, Li J. Application Value of Real-Time Ultrasonic Elastograph with Serum Human Epididymis Protein 4, Interleukin-33, and Carbohydrate Antigen 153 in Diagnosis of Early Cervical Cancer. J Healthc Eng. 2022 Apr 12;2022:4880874. doi: 10.1155/2022/4880874.
6. Hwang WY, Suh DH, Kim K, Kim YB, No JH. Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer. Cancer Control. 2022 Jan-Dec;29:10732748221097778. doi: 10.1177/10732748221097778.
7. Momenimovahed Z, Mazidimoradi A, Allahqoli L, Salehiniya H. The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review. Cancer Rep (Hoboken). 2025 Mar;8(3):e70142. doi: 10.1002/cnr2.70142.
8. Papadatou K, Perros P, Thomakos N, Haidopoulos D, Rodolakis A, Pergialiotis V. Biomarkers in Cervical Cancer. Hellenic Journal of Obstetrics & Gynecology. 2022;21(14): doi: 10.33574/hjog.0401.
9. Pînzaru V, Mărițoi T, David V, Foca E, Șaptefrați L. Expression of estrogen and progesterone receptors and their clinicopathological correlations in serous ovarian carcinoma. Mold J Health Sci. 2025;4(12):3-11. https://doi.org/1 0.52645/MJHS.2025.4.01.
10. Salim E, Zubairi AM, Danish SH, Ali U. Diagnostic Accuracy of Risk of Ovarian Malignancy Algorithm (ROMA) in Post-Menopausal Patients with Ovarian Mass. J Coll Physicians Surg Pak. 2018 Jun;28(6):440-444. doi: 10.29271/jcpsp.2018.06.440.
11. Serdar CC, Osmanoglu S. Comparison of CA-125 and HE4 in ovarian cancer recurrence detection. Acıbadem Univ. Sağlık Bilim. Derg. 2025;16(1):83-97. https://doi.org/10.31067/acusaglik.1539955
12. Shi H, Liu L, Deng X, Xing X, Zhang Y, Djouda Rebecca Y, et al. Exosomal biomarkers in the differential diagnosis of ovarian tumors: the emerging roles of CA125, HE4, and C5a. J Ovarian Res. 2024 Jan 5;17(1):4. doi: 10.1186/s13048-023-01336-6.
13. Shi Q, Xu L, Yang R, Meng Y, Qiu L. Ki-67 and P16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions. Oncol Lett. 2019 Aug;18(2):1351-1355. doi: 10.3892/ol.2019.10430.
14. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
15. Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019 Apr;43(2):135-144. doi: 10.1016/j.currproblcancer.2018.06.001.

Publication:

«World of Medicine and Biology» Vol. 22 No. 1 (2026) , с. 155-159
УДК 616.347/616.347-008.64:616.61

DOI:

https://doi.org/10.26724/2079-8334-2026-1-95-155-159